|
Market Closed -
Nasdaq
16:00:00 2026-11-04 EST
|
5-day change | 1st Jan Change | ||
| 22.80 USD | +3.83% |
|
-1.04% | +29.25% |
| 10-27 | Asian Equities Traded in the US as American Depositary Receipts Rise in Tuesday Trading | MT |
| 10-26 | Zai Lab's Lung Cancer Drug Achieves Promising Response Rate in Phase 1b Trial; Shares up 4% | MT |
Company Valuation: Zai Lab Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 6,059 | 2,946 | 2,688 | 2,853 | 1,962 | 2,831 | - | - |
| Change | - | -51.37% | -8.77% | 6.15% | -31.23% | 44.27% | - | - |
| Enterprise Value (EV) 1 | 4,650 | 1,938 | 1,897 | 2,095 | 1,397 | 2,322 | 2,382 | 2,525 |
| Change | - | -58.33% | -2.13% | 10.47% | -33.34% | 66.23% | 2.6% | 6.02% |
| P/E | -8.29x | -6.63x | -7.9x | -10.1x | -11x | -10.2x | -10.4x | -15.8x |
| PBR | 4.35x | - | 3.34x | 3.36x | 2.73x | 4.58x | 6.11x | 5.52x |
| PEG | - | 0.2x | 0.3x | 0.4x | 0.3x | -0.3x | 4.76x | 0.5x |
| Capitalization / Revenue | 42x | 13.7x | 10.1x | 7.15x | 4.26x | 6.56x | 5.17x | 3.97x |
| EV / Revenue | 32.2x | 9.01x | 7.11x | 5.25x | 3.04x | 5.38x | 4.35x | 3.55x |
| EV / EBITDA | -6.7x | -4.89x | -5.3x | -7.75x | -6.51x | -8.2x | -9.97x | -18.2x |
| EV / EBIT | -6.64x | -4.79x | -5.17x | -7.43x | -6.09x | -8.14x | -10.1x | -15.3x |
| EV / FCF | -8.19x | -4.94x | -9.23x | -9.5x | -8.5x | -13.2x | -13.3x | -20.7x |
| FCF Yield | -12.2% | -20.2% | -10.8% | -10.5% | -11.8% | -7.56% | -7.5% | -4.83% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -7.58 | -4.63 | -3.46 | -2.6 | -1.6 | -2.245 | -2.196 | -1.447 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 144.3 | 215 | 266.7 | 399 | 460.2 | 431.8 | 547.2 | 712.1 |
| EBITDA 1 | -693.6 | -396.1 | -357.5 | -270.3 | -214.4 | -283.2 | -239 | -138.7 |
| EBIT 1 | -700.1 | -404.4 | -366.6 | -282.1 | -229.4 | -285.3 | -236.4 | -165.4 |
| Net income 1 | -704.5 | -443.3 | -334.6 | -257.1 | -175.5 | -244.1 | -219.6 | -157.7 |
| Net Debt 1 | -1,409 | -1,008 | -791.3 | -757.9 | -565.3 | -508.9 | -448.5 | -305.1 |
| Reference price 2 | 62.85 | 30.70 | 27.33 | 26.19 | 17.64 | 22.80 | 22.80 | 22.80 |
| Nbr of stocks (in thousands) | 96,409 | 95,972 | 98,349 | 108,937 | 111,219 | 124,145 | - | - |
| Announcement Date | 3/1/22 | 3/1/23 | 2/27/24 | 2/27/25 | 2/26/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -9.78x | 5.14x | -7.83x | -.--% | 2.83B | |
| 41.24x | 13.94x | 30.97x | 0.48% | 1,263B | |
| 38.96x | 6.55x | 18.42x | 2.01% | 665B | |
| 36.79x | 8.37x | 17.26x | 2.42% | 521B | |
| 21.08x | 5.12x | 12.75x | 2.56% | 387B | |
| 95.75x | 5.88x | 25.02x | 2.35% | 371B | |
| 22.88x | 5.88x | 14.19x | 2.73% | 310B | |
| 24.26x | 4.85x | 13.68x | 1.8% | 293B | |
| 29.25x | 7.46x | 13.36x | 2.19% | 259B | |
| -40.09x | 7.32x | 45.96x | 1.97% | 216B | |
| Average | 26.03x | 7.05x | 18.38x | 1.85% | 428.82B | |
| Weighted average by Cap. | 35.89x | 8.69x | 22.47x | 1.73% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ZLAB Stock
- Valuation Zai Lab Limited
Select your edition
All financial news and data tailored to specific country editions
